# Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

> **NCT00752999** · PHASE2 · WITHDRAWN · sponsor: **Rigel Pharmaceuticals**

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Fostamatinib Disodium (R935788)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00752999
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-11
- **Primary completion:** 2009-11
- **Final completion:** 2010-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was withdrawn for business reasons before study start.
- **Last updated:** 2012-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752999, "Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00752999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*